Portage Biotech
Portage Biotech is a clinical-stage immuno-oncology company dedicated to developing first-in-class therapies that target known checkpoint resistance pathways to achieve durable treatment responses and improve quality of life for cancer patients. With a diverse portfolio of drug platforms and a strong industry network, Portage aims to revolutionize cancer research and development. The team has a successful track record, including contributions to five oncology drug approvals and high-value exits, and employs a fail-fast approach to select the most promising assets for clinical development. The company is advancing multiple programs, including immunotherapies, adenosine inhibitors, nanolipogels, and virus-like particles, with a focus on enhancing immune responses and overcoming resistance in cancer treatments.
Industries
Nr. of Employees
small (1-50)
Portage Biotech
British Virgin Islands, Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, VG1110
Products
Liposomal iNKT engager (small-molecule iNKT agonist formulation)
Liposomal formulation of a small-molecule invariant natural killer T (iNKT) engager designed to activate innate and adaptive anti-tumor immunity and be used alone or in combination with checkpoint inhibitors.
Adenosine receptor inhibitor suite (A2A/A2B small-molecule inhibitors)
A portfolio of small-molecule inhibitors targeting A2A, A2B, or both receptors to reduce adenosine-mediated immunosuppression in the tumor microenvironment.
Nanolipogel co-formulation platform
A nanolipogel-based co-formulation platform for loading and controlled release of multiple therapeutic modalities within the tumor microenvironment to enable single-medicine combination treatments.
VLP-based STING agonist delivery platform
Virus-like particle (VLP) delivery system formulated to carry STING pathway agonists for systemic administration and targeted activation of dendritic cells.
Liposomal iNKT engager (small-molecule iNKT agonist formulation)
Liposomal formulation of a small-molecule invariant natural killer T (iNKT) engager designed to activate innate and adaptive anti-tumor immunity and be used alone or in combination with checkpoint inhibitors.
Adenosine receptor inhibitor suite (A2A/A2B small-molecule inhibitors)
A portfolio of small-molecule inhibitors targeting A2A, A2B, or both receptors to reduce adenosine-mediated immunosuppression in the tumor microenvironment.
Nanolipogel co-formulation platform
A nanolipogel-based co-formulation platform for loading and controlled release of multiple therapeutic modalities within the tumor microenvironment to enable single-medicine combination treatments.
VLP-based STING agonist delivery platform
Virus-like particle (VLP) delivery system formulated to carry STING pathway agonists for systemic administration and targeted activation of dendritic cells.
Services
Strategic counsel and program management guiding novel immuno-oncology assets from discovery through human proof-of-concept, including asset selection and partner readiness.
Sponsorship and operational execution support for early-stage oncology trials, including combination studies with external checkpoint inhibitors.
Execution of IND-enabling preclinical studies and coordination of regulatory activities required to support clinical entry.
Development of co-formulated delivery systems (nanolipogels, liposomes, PLGA formulations, VLPs) to enable co-delivery, targeted release, and reduced systemic exposure.
Strategic counsel and program management guiding novel immuno-oncology assets from discovery through human proof-of-concept, including asset selection and partner readiness.
Sponsorship and operational execution support for early-stage oncology trials, including combination studies with external checkpoint inhibitors.
Execution of IND-enabling preclinical studies and coordination of regulatory activities required to support clinical entry.
Development of co-formulated delivery systems (nanolipogels, liposomes, PLGA formulations, VLPs) to enable co-delivery, targeted release, and reduced systemic exposure.
Expertise Areas
- Immuno-oncology clinical development
- Formulation development and co-delivery platforms
- Preclinical pharmacology and translational research
- Small-molecule immunomodulator discovery (iNKT and adenosine pathways)
Key Technologies
- Nanolipogel co-formulations
- Liposomal drug delivery
- PLGA nanoparticle co-formulations
- Virus-like particle (VLP) delivery